Published on: BUSINESS WIRE
Mar 07, 2016
Newly established innovation division at Seegene Technologies will deliver customized assays of increased complexity while maintaining sensitivity, specificity, and cost-effectiveness for U.S. market
Seegene Technologies, Inc., a wholly-owned subsidiary of Seegene, Inc. (096530. KQ), a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), is making Seegene’s proprietary multiplex PCR assay technology available for innovative research applications in the U.S. Seegene Technologies will be responsible for leading the U.S. strategy as the company evaluates opportunities for its existing portfolio of CE-marked in vitro diagnostics (IVD) products in the market.
The company made the announcement today at the 2016 Molecular Medicine Tri-Conference (Tri-Con) in San Francisco. This marks the official launch of its U.S. custom services and innovation division to better serve its customers and partnerships for molecular diagnostic development, clinical and translational research, and other life science and agricultural applications. With company headquarters in Seoul, South Korea, this new division will serve as the technology innovation arm of the parent corporation. The U.S. offices are located in Concord, California.
According to Dr. Jong-Yoon Chun, CEO and Founder of Seegene, “Our success at providing complex, yet cost-effective, multiplex PCR molecular diagnostic assays throughout Europe, Asia, Canada, Middle East and Latin America provides us with a solid foundation from which to build on to serve the U.S. market as well.”
Seegene’s technology and clinical utility will be demonstrated during two speaker presentations during Tri-Con, both of which are open to the press:
“‘Fit-for-Workflow’ considerations for designing multiplex PCR assays for SNP detection and target enrichment,” led by Young Kim, Ph.D., Lead Application Scientist, Seegene is scheduled on Tuesday, March 8 at 3:40 p.m. PST. Conventional approaches to assay development using PCR are generally limited to very few targets, which is not an ideal companion to NGS. Using examples from BCR-ABL, thrombosis, HPV genotyping, and others, we will discuss novel approaches to develop high-multiplex RT-PCR and qPCR assays that achieve high-throughput, target complexity, specificity and sensitivity.
“Molecular Diagnostics for Infectious Disease Advancing Microbial Diagnostics to Improve Detection and Patient Outcome,” led by Diane Hirigoyen, M.S., Lead Molecular Specialist, University of Minnesota, Hennepin County Medical Center (HCMC), will be a lunch symposium beginning at 12:40 p.m. PST on Wednesday, March 9, 2016. The session will include a discussion about the increase in the incidence of active TB among certain U.S. populations, resulting in increased detection of multi-drug resistant (MDR) and extreme resistant (XDR) strains of TB as a result. The session will share the experience of The Mycobacteriology Laboratory at HCMC and results on the emergence of TB and TB-like diseases in an inner city and active immigrant community.